Compare Stocks: FBIO, EBS, VNDA, and SABS

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
EBS Emergent Biosolutions	$7.41 +2.6%	$8.04	$5.61 ▼ $14.06	$372.52M	2.35	677,259 shs	441,012 shs
FBIO Fortress Biotech	$2.76 -11.8%	$3.06	$1.79 ▼ $4.53	$103.98M	1.21	582,133 shs	2.31 million shs
SABS SAB Biotherapeutics	$3.79 +6.2%	$3.67	$1.85 ▼ $5.15	$272.98M	0.53	523,631 shs	676,195 shs
VNDA Vanda Pharmaceuticals	$5.23 +2.5%	$5.89	$4.14 ▼ $9.94	$306.69M	0.6	833,436 shs	719,844 shs

7 Stocks That Could Lead the Next Market Boom

Tesla, Nvidia, and Google helped shape the last era of market growth, but the next wave could come from a new group of companies. Inside this report, you’ll find 7 stocks that could play a major role in the next tech-driven market boom.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
EBS Emergent Biosolutions	0.00%	-1.07%	-13.04%	-15.05%	+27.98%
FBIO Fortress Biotech	0.00%	-6.29%	+2.96%	+34.33%	+72.93%
SABS SAB Biotherapeutics	0.00%	+1.71%	-8.93%	+2.88%	+60.09%
VNDA Vanda Pharmaceuticals	0.00%	-1.54%	-17.87%	-27.14%	+21.72%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
EBS Emergent Biosolutions	$7.41 +2.6%	$8.04	$5.61 ▼ $14.06	$372.52M	2.35	677,259 shs	441,012 shs
FBIO Fortress Biotech	$2.76 -11.8%	$3.06	$1.79 ▼ $4.53	$103.98M	1.21	582,133 shs	2.31 million shs
SABS SAB Biotherapeutics	$3.79 +6.2%	$3.67	$1.85 ▼ $5.15	$272.98M	0.53	523,631 shs	676,195 shs
VNDA Vanda Pharmaceuticals	$5.23 +2.5%	$5.89	$4.14 ▼ $9.94	$306.69M	0.6	833,436 shs	719,844 shs

7 Stocks That Could Lead the Next Market Boom

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
EBS Emergent Biosolutions	0.00%	-1.07%	-13.04%	-15.05%	+27.98%
FBIO Fortress Biotech	0.00%	-6.29%	+2.96%	+34.33%	+72.93%
SABS SAB Biotherapeutics	0.00%	+1.71%	-8.93%	+2.88%	+60.09%
VNDA Vanda Pharmaceuticals	0.00%	-1.54%	-17.87%	-27.14%	+21.72%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
EBS Emergent Biosolutions	2.40	Hold	$12.00	62.05% Upside
FBIO Fortress Biotech	2.25	Hold	$17.00	515.94% Upside
SABS SAB Biotherapeutics	2.73	Moderate Buy	$12.00	216.62% Upside
VNDA Vanda Pharmaceuticals	2.50	Moderate Buy	$14.30	173.42% Upside

Current Analyst Ratings Breakdown

Latest FBIO, EBS, VNDA, and SABS Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
7/17/2026	VNDA Vanda Pharmaceuticals	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (D-)
7/8/2026	FBIO Fortress Biotech	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (D)
7/8/2026	SABS SAB Biotherapeutics	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (D+)
6/24/2026	SABS SAB Biotherapeutics	Barclays Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Initiated Coverage	Overweight	$13.00
6/17/2026	SABS SAB Biotherapeutics	Chardan Capital Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Buy	$14.00 ➝ $16.00
6/15/2026	SABS SAB Biotherapeutics	Leerink Partners Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Outperform	$7.00 ➝ $12.00
6/15/2026	SABS SAB Biotherapeutics	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy	$10.00
6/4/2026	VNDA Vanda Pharmaceuticals	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy
6/2/2026	EBS Emergent Biosolutions	UBS Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy
6/2/2026	EBS Emergent Biosolutions	Benchmark Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy
5/22/2026	SABS SAB Biotherapeutics	Citigroup Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Initiated Coverage	Buy	$11.00

(Data available from 8/3/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
EBS Emergent Biosolutions	$742.90M	0.51	$3.76 per share	1.97	$9.95 per share	0.74
FBIO Fortress Biotech	$63.26M	1.45	N/A	N/A	$2.00 per share	1.38
SABS SAB Biotherapeutics	$1.32M	219.53	$0.36 per share	10.45	$3.18 per share	1.19
VNDA Vanda Pharmaceuticals	$217.78M	1.44	N/A	N/A	$5.54 per share	0.94

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
EBS Emergent Biosolutions	$52.60M	-$0.28	N/A	N/A	N/A	-1.27%	10.76%	4.22%	8/5/2026 (Estimated)
FBIO Fortress Biotech	$6.82M	$3.17	0.87	N/A	N/A	193.12%	109.66%	45.56%	8/13/2026 (Estimated)
SABS SAB Biotherapeutics	$13.27M	-$2.11	N/A	N/A	N/A	N/A	-0.29%	-0.25%	8/6/2026 (Estimated)
VNDA Vanda Pharmaceuticals	-$220.47M	-$4.05	N/A	N/A	N/A	-109.99%	-32.26%	-23.43%	8/5/2026 (Estimated)

Latest FBIO, EBS, VNDA, and SABS Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/13/2026	Q2 2026	FBIO Fortress Biotech	-$0.20	N/A	N/A	N/A	$18.30 million	N/A
8/6/2026	Q2 2026	SABS SAB Biotherapeutics	-$0.29	N/A	N/A	N/A	$0.13 million	N/A
8/5/2026	Q2 2026	EBS Emergent Biosolutions	-$0.0850	N/A	N/A	N/A	$177.50 million	N/A
8/5/2026	Q2 2026	VNDA Vanda Pharmaceuticals	-$0.5825	N/A	N/A	N/A	$61.93 million	N/A
5/14/2026	Q1 2026	FBIO Fortress Biotech	-$0.22	$2.82	+$3.04	$2.82	$16.34 million	$16.04 million
5/12/2026	Q1 2026	SABS SAB Biotherapeutics	-$0.20	-$0.35	-$0.15	-$0.35	$0.13 million	N/A
5/6/2026	Q1 2026	VNDA Vanda Pharmaceuticals	-$0.6880	-$0.82	-$0.1320	-$0.82	$54.98 million	$51.72 million

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
EBS Emergent Biosolutions	N/A	N/A	N/A	N/A	N/A
FBIO Fortress Biotech	N/A	N/A	N/A	N/A	N/A
SABS SAB Biotherapeutics	N/A	N/A	N/A	N/A	N/A
VNDA Vanda Pharmaceuticals	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
EBS Emergent Biosolutions	1.10	4.29	2.08
FBIO Fortress Biotech	0.18	2.86	2.77
SABS SAB Biotherapeutics	0.01	11.45	11.45
VNDA Vanda Pharmaceuticals	0.01	2.16	2.15

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
EBS Emergent Biosolutions	78.40%
FBIO Fortress Biotech	96.51%
SABS SAB Biotherapeutics	7.82%
VNDA Vanda Pharmaceuticals	88.14%

Insider Ownership

Company	Insider Ownership
EBS Emergent Biosolutions	6.00%
FBIO Fortress Biotech	28.50%
SABS SAB Biotherapeutics	7.39%
VNDA Vanda Pharmaceuticals	10.70%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
EBS Emergent Biosolutions	2,420	51.60 million	48.50 million	Optionable
FBIO Fortress Biotech	170	33.22 million	23.75 million	Optionable
SABS SAB Biotherapeutics	140	76.46 million	70.81 million	Not Optionable
VNDA Vanda Pharmaceuticals	290	60.14 million	53.70 million	Optionable

FBIO, EBS, VNDA, and SABS Headlines

Recent News About These Companies

Renaissance Technologies LLC Raises Stake in Vanda Pharmaceuticals Inc. $VNDA

July 30, 2026 | marketbeat.com

Vanda Pharmaceuticals Inc. (VNDA) Stock Price, News, Quote & History - Yahoo Finance

July 29, 2026 | finance.yahoo.com

Vanda Pharmaceuticals to Announce Second Quarter 2026 Financial Results on August 5, 2026

July 29, 2026 | prnewswire.com

Vanda Pharmaceuticals (VNDA) to Post Earnings on Thursday

July 23, 2026 | marketbeat.com

Vanda Pharmaceuticals Inc. (NASDAQ:VNDA) Receives Average Rating of "Moderate Buy" from Brokerages

July 19, 2026 | marketbeat.com

Vanda Pharmaceuticals: Risks Rising, Rewards Dwindling - Why I'm Downgrading To Hold

July 17, 2026 | seekingalpha.com

Vanda Pharmaceuticals Announces EMA Positive Opinion for Orphan Drug Designation of Imsidolimab for Generalized Pustular Psoriasis - A Milestone Recognition of GPP as a ...

July 17, 2026 | uk.finance.yahoo.com

Vanda Pharmaceuticals Announces EMA Positive Opinion for Orphan Drug Designation of Imsidolimab for Generalized Pustular Psoriasis - A Milestone Recognition of GPP as a Distinct Rare Disease in Europe

July 16, 2026 | prnewswire.com

NEREUS™ Powers Forward: Sponsors No. 47 IndyCar Entry, Celebrating 47 Years Since Last New U.S. Motion Sickness Treatment

July 15, 2026 | prnewswire.com

Vanda Pharmaceuticals Announces Participation in the B. Riley Securities 2026 Mind, Muscle & Vision Summit

July 10, 2026 | prnewswire.com

Vanda Pharmaceuticals Inc. $VNDA is AIGH Capital Management LLC's 7th Largest Position

July 9, 2026 | marketbeat.com

Vanda Pharmaceuticals Inc.: Vanda Pharmaceuticals Announces FDA Rare Pediatric Disease Designation for Investigational Therapy for Charcot-Marie-Tooth Disease Type 2S

July 8, 2026 | finanznachrichten.de

VNDA stock gains after-hours as FDA grants rare pediatric disease designation for experimental therapy

July 7, 2026 | msn.com

Vanda Pharmaceuticals Announces FDA Rare Pediatric Disease Designation for Investigational Therapy for Charcot-Marie-Tooth Disease Type 2S

July 7, 2026 | prnewswire.com

Here’s Why H.C. Wainwright Remains a Buy on Vanda Pharmaceuticals (VNDA)

July 3, 2026 | finance.yahoo.com

Here’s Why H.C. Wainwright Remains a Buy on Vanda Pharmaceuticals (VNDA)

July 3, 2026 | insidermonkey.com

5 Best Small-Cap Growth Stocks to Invest In Now

June 30, 2026 | insidermonkey.com

Vanda Shareholders Approve Directors, Auditor and Compensation Plans

June 5, 2026 | tipranks.com

Vanda Pharmaceuticals Announces Orphan Drug Designation in Japan for Imsidolimab in Generalized Pustular Psoriasis

May 27, 2026 | prnewswire.com

How The Vanda Pharmaceuticals (VNDA) Investment Story Is Shifting With BYSANTI And Nereus

May 18, 2026 | finance.yahoo.com

Vanda: A Long-Term Pharma Growth Idea, Despite Q1 Earnings Miss

May 13, 2026 | seekingalpha.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

FBIO, EBS, VNDA, and SABS Company Descriptions

Emergent Biosolutions NYSE:EBS

$7.40 +0.19 (+2.56%)

Closing price 03:59 PM Eastern

Extended Trading

$7.44 +0.04 (+0.47%)

As of 07:34 PM Eastern

Emergent BioSolutions Inc., a life sciences company, provides preparedness and response solutions for accidental, deliberate, and naturally occurring public health threats in the United States. The company offers NARCAN Nasal Spray for the emergency treatment of known or suspected opioid overdose; Vaxchora vaccine for the prevention of cholera; Vivotif vaccine for oral administration for the prevention of typhoid fever; Anthrasil for the treatment of inhalational anthrax; BioThrax, an anthrax vaccine; CYFENDUS for post-exposure prophylaxis of disease following suspected or confirmed exposure to Bacillus anthracis; and Raxibacumab injection for the treatment and prophylaxis of inhalational anthrax. It also provides ACAM2000, a smallpox vaccine; CNJ-016 to address complications from smallpox vaccination; TEMBEXA for the treatment of smallpox disease caused by variola virus in adult and pediatric patients; BAT for the treatment of symptomatic botulism; Ebanga for the treatment of Ebola; Reactive Skin Decontamination Lotion Kit to remove or neutralize chemical warfare agents from the skin; Trobigard, a atropine sulfate obidoxime chloride auto-injector. In addition, the company is developing CGRD-001 for the treatment of poisoning by organophosphorus nerve agents or organophosphorus compounds; EBS-LASV to prevent Lassa fever; EBS-MARV to prevent Marburg virus disease; EBS-SUDV to prevent Sudan virus disease; Pan-Ebola mAbs for the treatment of ebola virus; SIAN Antidote for initial treatment of certain or suspected acute cyanide poisoning; UniFlu for immunity against influenza A and B viruses; and WEVEE-VLP for equine encephalitis virus infections. Further, it provides contract development and manufacturing services comprising drug substance and product manufacturing, and packaging, as well as technology transfer, process, and analytical development services. The company was incorporated in 1998 and is headquartered in Gaithersburg, Maryland.

Fortress Biotech NASDAQ:FBIO

$2.76 -0.37 (-11.82%)

Closing price 04:00 PM Eastern

Extended Trading

$2.82 +0.06 (+1.99%)

As of 07:34 PM Eastern

Fortress Biotech, Inc., a biopharmaceutical company, develops dermatology, pharmaceutical, and biotechnology products in the United States. The company markets dermatology products, such as Qbrexza a medicated cloth towelette for the treatment of primary axillary hyperhidrosis; Accutane capsules for severe recalcitrant nodular acne; Amzeeq for severe acne vulgaris; Zilxi, a topical foam; Exelderm cream and solution for topical use; Targadox an oral doxycycline drug for adjunctive therapy for severe acne; Luxamend; sulconazole nitrate cream and solution for tinea cruris and tinea corporis; and doxycycline hyclate tablet. It also develops late stage product candidates, such as intravenous Tramadol for the treatment of post-operative acute pain; CUTX-101, an injection for the treatment of Menkes disease; Cosibelimab for metastatic cancers; Olafertinib for the treatment of patients with EGFR mutation-positive NSCLC; CAEL-101 for the treatment of amyloid light chain amyloidosis; Triplex vaccine for cytomegalovirus; and DFD-29 for the treatment of rosacea. The company's early stage product candidates include Dotinurad for gout; MB-106 for B-cell non-hodgkin lymphoma; MB-101 for glioblastoma; MB-108 for recurrent GBM; MB-109 for refractory glioblastoma; AJ201, an androgen receptor degradation enhancer; BAER-101, a positive allosteric modulator; MB-117 for newly diagnosed x-linked severe combined immunodeficiency; and MB217 for previously transplanted; and MB-110 for RAG1 severe combined immunodeficiency. Its preclinical product candidates comprise Mayo Clinic In Vivo CAR T Platform Technology; AAV-ATP7A gene therapy; AVTS-001 gene therapy; CK-103 BET inhibitor; CEVA-D and CEVA-102; CK-302, an anti-GITR; CK-303, an anti-CAIX; and oligonucleotide platform. The company was formerly known as Coronado Biosciences, Inc. and changed its name to Fortress Biotech, Inc. in April 2015. Fortress Biotech, Inc. was incorporated in 2006 and is based in Bay Harbor Islands, Florida.

SAB Biotherapeutics NASDAQ:SABS

$3.79 +0.22 (+6.16%)

Closing price 04:00 PM Eastern

Extended Trading

$3.76 -0.04 (-0.92%)

As of 07:54 PM Eastern

SAB Biotherapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of human polyclonal immunotherapeutic antibodies to address immune system disorders and infectious diseases. It has applied advanced genetic engineering and antibody science to develop transchromosomic bovine herds that produce fully human antibodies targeted at infectious diseases and immune and autoimmune disorders, including infectious diseases, influenza, CDI, type 1 diabetes, organ transplantation, and oncology, as well as immunology, gastroenterology, and respiratory diseases. The company also uses its DiversitAb immunotherapy platform to produce fully-human polyclonal antibodies without the need for human donors or plasma. In addition, its lead product candidate SAB-142, a human, multi-target anti-thymocyte globulin treatment, currently under Phase 1 trials in delaying the onset or progression of type 1 diabetes. Further, the company develops SAB-176, a multivalent, broadly neutralizing - human polyclonal immunoglobulin therapeutic candidate, currently in Phase 2a development for the treatment or prevention of severe influenza. SAB Biotherapeutics, Inc. was founded in 2014 and is headquartered in Miami Beach, Florida.

Vanda Pharmaceuticals NASDAQ:VNDA

$5.23 +0.13 (+2.55%)

Closing price 04:00 PM Eastern

Extended Trading

$5.16 -0.07 (-1.24%)

As of 07:34 PM Eastern

Vanda Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of therapies to address high unmet medical needs worldwide. The company's marketed products include HETLIOZ to treat non-24-hour sleep-wake disorders; and Fanapt oral tablets for the treatment of schizophrenia. Its pipeline products include HETLIOZ (tasimelteon) to treat jet lag disorder, insomnia, delayed sleep phase disorder, sleep disturbances in autism spectrum disorder, and pediatric Non-24; Fanapt (iloperidone) for the treatment of bipolar I disorder and Parkinson's disease psychosis, as well as a long acting injectable (LAI) formulation to treat schizophrenia; and Tradipitant (VLY-686), a small molecule neurokinin-1 receptor (NK-1R) antagonist to treat gastroparesis, motion sickness, atopic dermatitis, and COVID-19 pneumonia. The company's pipeline products also include VTR-297, a small molecule histone deacetylase inhibitor to treat hematologic malignancies and with potential use as a treatment for various oncology indications; VQW-765, a small molecule nicotinic acetylcholine receptor partial agonist to treat performance anxiety and psychiatric disorders; VHX-896, an active metabolite of iloperidone; and antisense oligonucleotide molecules. In addition, it offers a portfolio of cystic fibrosis transmembrane conductance regulator activators and inhibitors that include VSJ-110 for the treatment of dry eye and ocular inflammation; and VPO-227 for the treatment of secretory diarrhea disorders comprising cholera. Vanda Pharmaceuticals Inc. was incorporated in 2002 and is headquartered in Washington, the District of Columbia.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest FBIO, EBS, VNDA, and SABS Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest FBIO, EBS, VNDA, and SABS Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

FBIO, EBS, VNDA, and SABS Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

FBIO, EBS, VNDA, and SABS Company Descriptions

Emergent Biosolutions NYSE:EBS

Fortress Biotech NASDAQ:FBIO

SAB Biotherapeutics NASDAQ:SABS

Vanda Pharmaceuticals NASDAQ:VNDA

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest FBIO, EBS, VNDA, and SABS Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest FBIO, EBS, VNDA, and SABS Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

FBIO, EBS, VNDA, and SABS Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

FBIO, EBS, VNDA, and SABS Company Descriptions

Emergent Biosolutions NYSE:EBS

Fortress Biotech NASDAQ:FBIO

SAB Biotherapeutics NASDAQ:SABS

Vanda Pharmaceuticals NASDAQ:VNDA

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools